JP6901479B2 - Ｃｘｃｒ２の阻害剤 - Google Patents

Ｃｘｃｒ２の阻害剤 Download PDF

Info

Publication number
JP6901479B2
JP6901479B2 JP2018526187A JP2018526187A JP6901479B2 JP 6901479 B2 JP6901479 B2 JP 6901479B2 JP 2018526187 A JP2018526187 A JP 2018526187A JP 2018526187 A JP2018526187 A JP 2018526187A JP 6901479 B2 JP6901479 B2 JP 6901479B2
Authority
JP
Japan
Prior art keywords
cancer
group
alkyl
pharmaceutically acceptable
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018526187A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534329A (ja
JP2018534329A5 (OSRAM
Inventor
チェン シー
チェン シー
アール．ドラゴリ ディーン
アール．ドラゴリ ディーン
ファン ジュンファ
ファン ジュンファ
カリシアク ヤロスラフ
カリシアク ヤロスラフ
レディ レレティ マンモハン
レディ レレティ マンモハン
マラソン ビーンクハム
マラソン ビーンクハム
マクマホン ジェフリー
マクマホン ジェフリー
田中　裕子
裕子 田中
ヤン チュ
ヤン チュ
ユイ チャオ
ユイ チャオ
ジャーン ペングリー
ジャーン ペングリー
マリ ベンカット
マリ ベンカット
Original Assignee
ケモセントリックス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス，インコーポレイティド filed Critical ケモセントリックス，インコーポレイティド
Publication of JP2018534329A publication Critical patent/JP2018534329A/ja
Publication of JP2018534329A5 publication Critical patent/JP2018534329A5/ja
Application granted granted Critical
Publication of JP6901479B2 publication Critical patent/JP6901479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018526187A 2015-11-19 2016-11-17 Ｃｘｃｒ２の阻害剤 Active JP6901479B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257529P 2015-11-19 2015-11-19
US62/257,529 2015-11-19
PCT/US2016/062427 WO2017087610A1 (en) 2015-11-19 2016-11-17 Inhibitors of cxcr2

Publications (3)

Publication Number Publication Date
JP2018534329A JP2018534329A (ja) 2018-11-22
JP2018534329A5 JP2018534329A5 (OSRAM) 2019-12-26
JP6901479B2 true JP6901479B2 (ja) 2021-07-14

Family

ID=58717757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526187A Active JP6901479B2 (ja) 2015-11-19 2016-11-17 Ｃｘｃｒ２の阻害剤

Country Status (20)

Country Link
US (4) US9809581B2 (OSRAM)
EP (1) EP3377059B1 (OSRAM)
JP (1) JP6901479B2 (OSRAM)
KR (1) KR102725791B1 (OSRAM)
CN (1) CN108601766B (OSRAM)
AR (1) AR106757A1 (OSRAM)
AU (1) AU2016355654B2 (OSRAM)
BR (1) BR112018010118B1 (OSRAM)
CA (1) CA3005737C (OSRAM)
DK (1) DK3377059T3 (OSRAM)
EA (1) EA035417B1 (OSRAM)
ES (1) ES2841912T3 (OSRAM)
IL (1) IL259354B (OSRAM)
MX (1) MX382779B (OSRAM)
PL (1) PL3377059T3 (OSRAM)
PT (1) PT3377059T (OSRAM)
SG (1) SG11201804136SA (OSRAM)
TW (1) TWI724056B (OSRAM)
WO (1) WO2017087610A1 (OSRAM)
ZA (1) ZA201803436B (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN110087530A (zh) 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
AU2018256436B2 (en) 2017-04-19 2024-12-05 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
WO2018200571A1 (en) 2017-04-25 2018-11-01 Arbutus Biopharma Corporation Substituted 2,3-dihydro-1h-indene analogs and methods using same
WO2019036374A1 (en) 2017-08-14 2019-02-21 Allergan, Inc. 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND THEIR USE
CN111867579B (zh) 2018-01-08 2023-11-24 凯莫森特里克斯股份有限公司 Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法
CN112292138A (zh) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Car t细胞的使用方法
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
US12083118B2 (en) 2018-03-29 2024-09-10 Arbutus Biopharma Corporation Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
WO2020047030A1 (en) * 2018-08-29 2020-03-05 Chemocentryx, Inc. Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors
IL281634B2 (en) 2018-09-21 2025-02-01 Pfizer Modified diisocyclobutenylamino-3-hydroxy-picolinamide and its use as a CCR6 inhibitor
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
US12486240B2 (en) * 2019-04-08 2025-12-02 Pi Industries Ltd. Oxadiazole compounds for controlling or preventing phytopathogenic fungi
CN114096524B (zh) * 2019-05-15 2025-03-04 阿龙拜欧有限公司 用于治疗癌症、抑制趋化因子活性和/或诱导细胞死亡的小分子
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
CN112274511B (zh) * 2019-07-22 2024-04-02 正大天晴药业集团股份有限公司 用于治疗移植物抗宿主病的喹啉衍生物
CN114585359B (zh) 2019-10-16 2025-08-12 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯酰胺
US11866429B2 (en) 2019-10-16 2024-01-09 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN113018438B (zh) * 2019-12-24 2022-06-17 四川大学 Cxcr2抑制剂在制备治疗鼻咽癌的药物中的用途
CN114929225B (zh) * 2020-01-19 2024-06-28 正大天晴药业集团股份有限公司 用于治疗类风湿性关节炎的喹啉衍生物
WO2021222818A2 (en) * 2020-04-30 2021-11-04 Gordon Erlinda M Damage-targeted treatments of disease
CN113995839B (zh) * 2021-10-11 2023-03-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Cxcr2抑制剂在改善肿瘤免疫微环境中的应用
CN113952453B (zh) * 2021-10-11 2023-01-24 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Cxcr2抑制剂在制备治疗肿瘤的药物中的应用
WO2024144816A1 (en) * 2022-12-30 2024-07-04 Cantex Pharmaceuticals, Inc. Treatment of immunologically cold solid tumors
WO2025149577A1 (en) * 2024-01-11 2025-07-17 Julius-Maximilians-Universitaet Wuerzburg 18f-cxcr2 pet tracer

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US6166050A (en) 1998-12-14 2000-12-26 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4
AR033803A1 (es) 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
EP1284956A4 (en) 2000-05-30 2005-08-24 Smithkline Beecham Corp ANTAGONISTS OF THE IL-8 RECEPTOR
ES2276926T3 (es) 2001-01-16 2007-07-01 Smithkline Beecham Corporation Antagonistas del receptor de il-8.
US20040132694A1 (en) 2001-01-16 2004-07-08 Palovich Michael R. Il-8 receptor antagonists
CN1575273A (zh) 2001-02-02 2005-02-02 先灵公司 作为cxc趋化因子受体拮抗剂的3.4－二－取代环丁烯－1,2－二酮类化合物
US20030204085A1 (en) 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
MXPA03009441A (es) 2001-04-16 2004-02-12 Schering Corp Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc.
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
WO2003080053A1 (en) 2002-03-18 2003-10-02 Schering Corporation Combination treatments for chemokine-mediated diseases
CN101514168B (zh) 2003-04-18 2014-02-26 默沙东公司 苯甲酰胺取代的二氧代环丁烯的合成
PE20051093A1 (es) 2004-01-30 2006-01-16 Schering Corp Polimorfos cristalinos de un ligando receptor de cxc quimiocina
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
DE102005035742A1 (de) 2005-07-29 2007-02-01 Merck Patent Gmbh Quadratsäurederivate II
CA2657051A1 (en) * 2006-07-07 2008-01-10 Schering Corporation 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
WO2008055570A1 (de) 2006-11-07 2008-05-15 Thyssenkrupp Drauz Nothelfer Gmbh Verfahren und anlage zum herstellen von verstärkten blechplatinen
MX2009009540A (es) 2007-03-07 2009-09-16 Alantos Pharm Holding Inhibidores de metaloproteasa que contienen una porcion heterociclica.
FR2915147B1 (fr) 2007-04-17 2010-01-15 Peugeot Citroen Automobiles Sa Siege pour vehicule automobile convertible en siege enfant dos a la route et vehicule automobile associe.
WO2008148790A1 (en) 2007-06-06 2008-12-11 Novartis Ag Anti -inflammatory substituted cyclobutenedione compounds
CA2692269A1 (en) 2007-07-03 2009-01-08 Schering Corporation Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds
CN101778836A (zh) 2007-07-05 2010-07-14 先灵公司 在1,2-取代的3,4-二氧-1-环丁烯化合物中控制的晶体大小的方法
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
EP2215074B1 (en) 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
MX2010006089A (es) 2007-12-04 2010-09-22 Schering Corp Metodos de tratamiento de enfermedad pulmonar obstructiva cronica.
EP2318369A1 (en) 2008-06-24 2011-05-11 TopoTarget A/S Squaric acid derivatives as inhibitors of the nicotinamide
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
AU2009303441A1 (en) 2008-10-16 2010-04-22 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010091543A1 (en) * 2009-02-10 2010-08-19 Merck Sharp & Dohme Corp. Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists
WO2010131145A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
SI2760821T1 (en) 2011-09-02 2018-02-28 Novartis Ag A salt salt of an anti-inflammatory substituted cyclobutenedione compound
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
AU2013265266A1 (en) 2012-05-23 2015-01-15 Stemergie Biotechnology Sa Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof
WO2015170430A1 (ja) 2014-05-08 2015-11-12 学校法人慶應義塾 大動脈解離後の炎症性障害抑制剤
US20170320954A1 (en) 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
CN111867579B (zh) 2018-01-08 2023-11-24 凯莫森特里克斯股份有限公司 Ccr6或cxcr2拮抗剂治疗泛发性脓疱型银屑病的方法

Also Published As

Publication number Publication date
US10370363B2 (en) 2019-08-06
CA3005737C (en) 2023-09-12
BR112018010118B1 (pt) 2023-10-31
IL259354A (en) 2018-07-31
WO2017087610A1 (en) 2017-05-26
EA035417B1 (ru) 2020-06-10
JP2018534329A (ja) 2018-11-22
US20180170916A1 (en) 2018-06-21
EP3377059A4 (en) 2019-03-20
MX382779B (es) 2025-03-13
US11040960B2 (en) 2021-06-22
US20200140418A1 (en) 2020-05-07
CA3005737A1 (en) 2017-05-26
BR112018010118A2 (pt) 2018-11-21
PT3377059T (pt) 2021-01-11
ES2841912T3 (es) 2021-07-12
IL259354B (en) 2021-05-31
EA201891211A1 (ru) 2018-12-28
CN108601766B (zh) 2022-05-13
KR20180100556A (ko) 2018-09-11
CN108601766A (zh) 2018-09-28
PL3377059T3 (pl) 2021-05-17
EP3377059B1 (en) 2020-10-21
NZ742819A (en) 2024-03-22
AU2016355654A1 (en) 2018-06-14
KR102725791B1 (ko) 2024-11-01
US11945805B2 (en) 2024-04-02
EP3377059A1 (en) 2018-09-26
US20170144996A1 (en) 2017-05-25
SG11201804136SA (en) 2018-06-28
TWI724056B (zh) 2021-04-11
TW201720816A (zh) 2017-06-16
US20220009911A1 (en) 2022-01-13
AR106757A1 (es) 2018-02-14
US9809581B2 (en) 2017-11-07
ZA201803436B (en) 2021-01-27
AU2016355654B2 (en) 2021-09-30
DK3377059T3 (da) 2021-01-11
MX2018006148A (es) 2019-06-12

Similar Documents

Publication Publication Date Title
JP6901479B2 (ja) Ｃｘｃｒ２の阻害剤
JP6923522B2 (ja) ケモカイン受容体のモジュレーター
EP3983064B1 (en) Cot modulators and methods of use thereof
WO2022140326A1 (en) Substituted indole compounds
WO2022140325A1 (en) 6-substituted indole compounds
US10550125B2 (en) Prodrugs of imidazotriazine compounds as CK2 inhibitors
HK1260688B (en) Inhibitors of cxcr2
HK1260688A1 (en) Inhibitors of cxcr2
HK40111115A (en) Cot modulators and methods of use thereof
JP2024533374A (ja) チエノピロール化合物
HK1262134B (en) Modulators of chemokine receptors
HK1262134A1 (en) Modulators of chemokine receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201013

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210518

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210617

R150 Certificate of patent or registration of utility model

Ref document number: 6901479

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250